Summary
A bioRxiv preprint reports that the accessibility and membrane organisation of cholesterol help control TLR4 signalling in microglia. The study identifies SR-B1 and sphingomyelin–cholesterol interactions as regulators of this inflammatory pathway.
A bioRxiv preprint reports that the way cholesterol is organised and made available within cell membranes helps determine how microglia activate the immune receptor TLR4. The researchers identify a sphingomyelin–cholesterol lipid complex, along with the cholesterol uptake receptor SR-B1, as regulators of this process.
The findings come from experimental work on microglial activation by lipopolysaccharide (LPS), a bacterial component commonly used to trigger innate immune signalling in laboratory systems. The authors describe the study as showing that cholesterol accessibility, rather than only the total amount of cholesterol in a cell, is an important control point for TLR4 signalling.
How cholesterol controls the TLR4 response
TLR4 activation requires the receptor to move into specialised regions of the cell membrane enriched in cholesterol and sphingolipids. These membrane regions help organise signalling proteins and can also support TLR4 internalisation, or endocytosis, after activation.
In the experiments described in the preprint, LPS increased cholesterol uptake and mobilisation in microglia. Blocking intracellular cholesterol trafficking, or inhibiting Aster, a transporter that moves cholesterol from the plasma membrane to the endoplasmic reticulum, reduced the inflammatory response.
The researchers identified SR-B1 as a mediator of the LPS-induced cholesterol uptake. Inhibiting SR-B1 suppressed several connected steps: TLR4 signalling, recruitment of the receptor to detergent-resistant membrane domains, and TLR4 endocytosis. These effects occurred without changing bulk cellular cholesterol, pointing to a change in how cholesterol was arranged or accessed rather than a simple increase or decrease in the cell’s total cholesterol.
The study used two molecular readouts to distinguish cholesterol pools. OlyA detected cholesterol associated with sphingomyelin, while D4H detected accessible cholesterol. SR-B1 inhibition remodelled the sphingolipid composition and expanded the sphingomyelin-associated cholesterol pool. LPS, in contrast, remodelled this pool and increased the accessible cholesterol signal.
The researchers also manipulated sphingomyelin–cholesterol interactions directly. These changes altered membrane properties and TLR4 trafficking, while stabilising the complexes suppressed inflammatory activation. Together, the results place lipid organisation upstream of the receptor’s movement and signalling behaviour.
Connection with disease-associated microglia
The preprint also reports an in-vivo component. LPS induced remodelling of sphingomyelin-associated cholesterol in microglia. Microglia carrying the Alzheimer’s disease-related ApoE4/Trem2R47H combination showed impaired remodelling of this cholesterol pool and stronger inflammatory responses.
This links the mechanism to a disease-associated microglial state without turning the finding into a treatment claim. Its immediate significance is mechanistic: the work suggests that signalling by an immune receptor can be regulated by the physical state and accessibility of membrane lipids, and that this control may be altered in Alzheimer’s disease-related microglia.
The study is a bioRxiv preprint, so it represents an early research report rather than a clinical study. The reported experiments concern lipid regulation of microglial TLR4 activation; translation into a human intervention would require further research. The supplied abstract also does not provide sample sizes or detailed experimental methods, limiting assessment of the individual effect estimates from the record alone.